The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Trends in analgesic consumption in France over the last 10 years and comparison of patterns across Europe
Open accessAbstract
Aims: The aims of the present study were to describe the consumption trends of three groups of analgesics (non‐opioids, and mild and strong opioids) between 2006 and 2015 in France, and compare this pattern of use with six European countries in 2015. Methods: Annual drugs sales were extracted from the French national authority's consumption database, and from the IMS Multinational Integrated Data Analysis System and national databases for European countries. Results: The use of mild opioids in France was found to have decreased by 53% over the past 10 years, owing to the declining use of dextropropoxyphene combinations, along with an increase in the use of non‐opioids and strong opioids (from 72 to 93, and 2 to 2.8 defined daily doses/1000 inhabitants/day, respectively). Paracetamol, the most consumed analgesic, increased over this period, particularly for the adult high dose (+140%). The use of tramadol and codeine combinations also increased, by 62% and 42%, respectively. Morphine remained the most used strong opioid, although there were also large increases in the consumption of oxycodone (+613%) and fentanyl (+263% and +72% for transmucosal and transdermal forms, respectively). A comparison of the patterns of use in Europe in 2015 showed a higher consumption of mild and strong opioids in the UK. France ranked first and third place, respectively, for paracetamol and mild opioid consumption, whereas its use of strong opioids was among the lowest. Conclusions: Paracetamol consumption is clearly highest in France, whereas its use of strong opioids is among the lowest in Europe, although its consumption of oxycodone has increased significantly. Further studies are required specifically to monitor these drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Survey of chronic pain in Europe: Prevalence, impact on daily life, and treatment
Breivik, H., Collett, B., Ventafridda, V., Cohen, R., & Gallacher, D. (2006) · European Journal of Pain · doi:10.1016/j.ejpain.2005.06.009 · Cited by 5,486
Pharmacological treatment of chronic pain—The need for CHANGE
Varrassi, G., Müller-Schwefe, G., Pergolizzi, J., Orónska, A., Morlion, B., Mavrocordatos, P., Margarit, C., Mangas, C., Jaksch, W., Huygen, F., et al. (2010) · Current Medical Research and Opinion · doi:10.1185/03007991003689175 · Cited by 167
Gedeborg, R., Svennblad, B., Holm, L., Sjögren, H., Bardage, C., Personne, M., Sjöberg, G., Feltelius, N., & Zethelius, B. (2017) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.4166 · Cited by 38
Cited by
Fekadu, S., Alemayehu, E., Dewil, R., & Van der Bruggen, B. (2019) · Science of The Total Environment · doi:10.1016/j.scitotenv.2018.11.072 · Cited by 499
Recent trends in life expectancy across high income countries: retrospective observational study
Ho, J. Y., & Hendi, A. S. (2018) · BMJ · doi:10.1136/bmj.k2562 · Cited by 439
Abundance, fate, and effects of pharmaceuticals and personal care products in aquatic environments
Adeleye, A. S., Xue, J., Zhao, Y., Taylor, A. A., Zenobio, J. E., Sun, Y., Han, Z., Salawu, O. A., & Zhu, Y. (2022) · Journal of Hazardous Materials · doi:10.1016/j.jhazmat.2021.127284 · Cited by 366
Paracetamol (acetaminophen): A familiar drug with an unexplained mechanism of action
Ayoub, S. S. (2021) · Temperature · doi:10.1080/23328940.2021.1886392 · Cited by 223
Gedeborg, R., Svennblad, B., Holm, L., Sjögren, H., Bardage, C., Personne, M., Sjöberg, G., Feltelius, N., & Zethelius, B. (2017) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.4166 · Cited by 38
Metadata
- Authors
- Hider‐Mlynarz, K., Cavalié, P., & Maison, P.
- Venue
- British Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 2018-04-02
- Volume
- 84
- Issue
- 6
- Pages
- 1324-1334
- ISSN
- 0306-5251 (ISSN-L)
- 1365-2125
- OpenAlex
- W2791970879
- Cited by
- 165
- References
- 3
- FWCI
- 23.83
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.